^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastroesophageal Cancer

    Related cancers:
    5d
    Concordance of Circulating Tumor DNA, Primary and Metastatic Tissue DNA, and Immunohistochemistry in Gastroesophageal Carcinoma. (PubMed, JCO Precis Oncol)
    ctDNA testing demonstrates high concordance with tDNA and IHC and offers faster turnaround. Given its minimally invasive nature and strong concordance with tissue-based testing, ctDNA is a reliable tool for genomic profiling and longitudinal monitoring in GEC.
    Retrospective data • Journal • MSi-H Biomarker • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • MSI (Microsatellite instability) • TYK2 (Tyrosine Kinase 2)
    |
    MSI-H/dMMR
    5d
    CP-IVX001: Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=70, Recruiting, ImmVirx Pty Ltd | Trial completion date: Nov 2026 --> Nov 2028 | Trial primary completion date: Sep 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    Tyvyt (sintilimab) • IVX037
    5d
    Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays (clinicaltrials.gov)
    P=N/A, N=420, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium
    6d
    Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients. (PubMed, Sci Rep)
    To explore whether ultra-sensitive circulating tumor DNA (ctDNA) profiling enables earlier prediction of treatment response and detection of disease progression, we applied NeXT Personal, an ultra-sensitive bespoke tumor-informed liquid biopsy platform, to profile tumor samples from the KeyLargo study, a phase II trial in which metastatic esophagogastric cancer (mEGC) patients received capecitabine, oxaliplatin, and pembrolizumab. Molecular progression (ctDNA increase) preceded imaging-derived progression by a median lead time of 65 days. These results suggest that ultra-sensitive liquid biopsy approaches could improve treatment decision-making for mEGC patients receiving chemotherapy and immunotherapy.
    Journal • Circulating tumor DNA
    |
    NeXT Personal™
    |
    Keytruda (pembrolizumab) • capecitabine • oxaliplatin
    7d
    A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors (clinicaltrials.gov)
    P1/2, N=150, Not yet recruiting, Astellas Pharma Global Development, Inc.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CLDN18 (Claudin 18)
    |
    HER-2 negative • CLDN18.2 expression
    7d
    A Study of Tooth Erosion in People With Esophagogastric Cancer (clinicaltrials.gov)
    P=N/A, N=174, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=300 --> 174 | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2026 --> Nov 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    11d
    IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    New P2 trial
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • arcotatug tavatecan (TAK-921)
    11d
    Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients (clinicaltrials.gov)
    P1, N=33, Completed, Arbele Pty Ltd | Recruiting --> Completed | N=68 --> 33 | Trial completion date: May 2026 --> Jul 2025 | Trial primary completion date: Mar 2026 --> Jul 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    CDH17 (Cadherin 17)
    |
    Tecentriq (atezolizumab) • cabotamig (ARB202)
    11d
    A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=310, Recruiting, Pfizer
    Trial initiation date
    12d
    A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=51, Not yet recruiting, Dong-A ST Co., Ltd.
    New P1 trial • First-in-human
    |
    CLDN18 (Claudin 18)
    13d
    HER-OIC: Perioperative Zanidatamab and Chemotherapy for HER2 Positive Gastroesophageal Cancer (clinicaltrials.gov)
    P1/2, N=29, Not yet recruiting, Universitaire Ziekenhuizen KU Leuven
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Tevimbra (tislelizumab-jsgr) • Ziihera (zanidatamab-hrii)
    13d
    GAMBIT: A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2 (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression • CLDN18.2 positive • CLDN1 positive
    |
    sonesitatug vedotin (AZD0901)